reason report
solid result net one-tim mg gather
momentum pt
bottom line alexion report financi result
consensu revenu ep
compani disclos soliri myasthenia gravi gmg
launch exceed expect alreadi contribut
quarter estim quarter support one-tim
benefit us demand pull ex-
us tender order revenu still would exceed consensu
without benefit alexion oper margin reach
quarter record sinc demonstr
impact compani restructur effort manag
increas element guidanc coupl gmg
trajectori anticip materi upward revis consensu
estim come week financi perform
benefit stock key upcom catalyst achiev
soliri neuromyel optica nmo phase trial year-
end launch likewis manag
life-cycl expans strategi consist improv
iv formul multipl subcutan dose formul
appear sensibl us increas expect
revenu durabl compani foundat franchis
increas revenu estim ep estim
consensu
higher longer term new price target
reiter outperform rate alexion stock
net debt total capit
price-to-earnings lt ep growth
averag dcf price-to-earnings
compani inform leerink partner llc research
revenu mm ep exclud option expens
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
price target rate stock
outperform alexion lead independ compani develop commerci
treatment ultra-rar disord complement system nineti percent revenu today
come soliri approv two differ rare diseas indic believ
alexion increas current revenu run rate complement franchis
competit threat soliri overst view given long safeti
efficaci histori soliri well alexion progress develop improv version
product greater potenc longer half-lif conveni dose beyond soliri alexion
still earli phase launch two addit rare diseas medicin kanuma
strensiq expect contribut approxim combin revenu
alexion maintain reason financi disciplin expect oper margin
bounc back better drop acquisit
synageva cost two product launch alexion remain
one fastest grow busi biopharmaceut durabl larg molecul
protein therapi believ recov multipl come quarter fail
trade discount reason cautiou outlook could becom one target
expect increasingli consolid industri
revenu beat consensu report organ alexion report total pro forma
revenu consensu forecast
embed within revenu tailwind pull-through us order due
juli holiday ex-u tender order us order
headwind much harder predict impact tender order futur quarter
soliri revenu consensu estim
soliri revenu increas yoy qoq strensiq revenu also
beat consensu estim kanuma revenu line
consensu miss estim
ep beat consensu reduc spend tax total non-gaap expens
less consensu estim driven sequenti
reduct quarter non-gaap sg revenu quarter
improv improv despit on-going
launch soliri gmg alexion tax rate two percentag point
consensu one percentag point expect report non-gaap ep
consensu estim
alexion increas aspect guidanc guid total revenu increas
includ increas soliri revenu guidanc
increas metabol franchis revenu
guidanc updat model midpoint
total revenu guidanc consensu alexion lower ratio guidanc
sg guidanc increas
oper margin guidanc revenu alexion also increas pro
forma ep guidanc updat model
midpoint pro forma ep consensu
plan alexion disclos us gmg patient soliri prior
quarter total patient enrol alexion one-
access program suggest commerci patient growth continu
year manag comment gate factor pull patient one sourc
commerci drug includ secur reimburs set vaccin period
identifi center receiv soliri infus patient us potenti
patient unrestrict commerci access prescrib patient treat
least one gmg patient soliri two metric caus manag remain confid
rate commerci uptak believ gmg contribut soliri revenu
us soliri sale global soliri sale term durat soliri manag
note real world proport non-respond significantli less observ
phase clinic trial manag fulli believ gmg launch surpass
revenu paroxysm nocturn hemoglobinuria pnh atyp hemolyt urem syndrom
ahu launch alexion plan initi phase gmg iv studi
pivot ahu trial slight delay iga nephropathi depriorit soliri
nmo readout confirm although file regulatori agenc pnh
pivot trial ahu yet read alexion confirm trial enrol may
announc call data releas delay alexion also
made decis depriorit develop iv iga nephropathi least
decis made maintain lower target expens year
maxim speed scope develop multipl subcutan
approach develop recent acquir wilson diseas program result
phase prevent trial investig soliri nmo still expect year-end
new high-dos formul plan could reduc infus time
hour minut alexion announc plan initi bridg studi formul
iv concentr could potenti sbla file
launch accord manag could reduc infus time
hour current formul minut hour sbla packag includ
compar clinic data consist pharmacokinet safeti immunogen
inform patient phase extens program also transfer higher
concentr dose believ strategi highlight alexion continu effort
innov support franchis well compani newfound willing pursu
everi avenu defend franchis current domin posit
subcutan studi initi alexion reiter guidanc expect
initi once-weekli qw subcutan version
smaller singl pk-base phase trial would support registr pnh ahu also
alexion announc plan begin initi clinic trial halozym enhanz drug-deliveri
technolog second sc formul product co-formul go
tradit drug develop protocol trial initi conduct
eu next-gener subcutan formul call
potenti extend dose interv qm
adjust revenu ep expect near term pt follow result
recent quarter made updat revenu earn forecast better
reflect compani oper go forward increas sale
due better perform launch gmg
total revenu forecast increas line
consensu longer term decreas oper expens
increas estim longer term reflect addit
expenditur result develop updat pro forma dilut
ep estim unchang longer term
consensu base
chang compani model peer compani multipl increas price
target maintain outperform rate alexion stock
price target base simpl averag three
approach believ reason basi valu stock today approach
simpl price earn multipl compar large-cap biopharma compani
discount cash flow dcf use rel multipl similar growth compani
ep appli ep estim alexion give fair valu
stock use expect ep compound-annual-growth-rate alexion period
current averag ratio larg molecul large-cap biotech give ep
multipl discount multipl compress alexion
appli ep estim give fair valu final dcf use
termin growth rate post give current valu averag
three valuat methodolog pt
risk view outlook valuat alexion includ major chang price
reimburs coverag label soliri compani main product today risk
includ commerci develop disappoint recent launch product strensiq
kanuma well develop disappoint addit indic soliri
successor complement inhibitor product final brand gener competitor
product soliri come market captur greater share caus greater market price
disrupt current expect futur outlook valuat would undermin
opportun better perform valu expect includ stronger initi
adopt recent launch new product forecast success develop
commerci new indic soliri beyond neuromyel optica
myasthenia gravi novel rare diseas medicin time horizon forecast
sale non-gaap
share count period dilut
guidanc
leerink partner research compani file zack factset consensu
leerink partner research compani file zack factset consensu
time
result pivot ahu
result pivot phase
leerink partner research compani report present clinicaltri gov
late stage pipelin program includ
late stage pipelin program exclud
million
leerink partner research compani file
million
good sold
 total revenu
sg total revenu
leerink partner research compani file
analysi stock price leerink target alexion
method today larg cap brand biopharma futur ep multipl ep
leerink estimate earn
current averag larg cap biopharma multipl ep
leerink adjust ep estim
capit
number period
impli target price
method leerink intrins valu base dcf current product net
current leerink dcf marketed/l stage program
current estim valu asset
method project forward earn multipl ep base ep
compound-annual-growth-rate larg cap biotech ratio
averag larg molecul larg cap biopharma co
impli ep multipl discount vs full multipl
averag method
leerink partner research compani file factset
